Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden von Hellmann, Matthew D, Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory A, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S, Brahmer, Julie, Reck, Martin, O’Byrne, Kenneth J, Geese, William J, Green, George, Chang, Han, Szustakowski, Joseph, Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis

Volltext

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study von Tabernero, J., Hozak, R.R., Yoshino, T., Cohn, A.L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D.C., Prausová, J., Muro, K., Siegel, R.W., Konrad, R.J., Ouyang, H., Melemed, S.A., Ferry, D., Nasroulah, F., Van Cutsem, E.

Volltext

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update von Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.

Volltext

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer von Peeters, M., Price, T.J., Cervantes, A., Sobrero, A.F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C.J.A., Strickland, A.H., Wilson, G., Ciuleanu, T.E., Roman, L., Van Cutsem, E., Tian, Y., Sidhu, R.

Volltext

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis von Borghaei, H., Ciuleanu, T.-E., Lee, J.-S., Pluzanski, A., Caro, R. Bernabe, Gutierrez, M., Ohe, Y., Nishio, M., Goldman, J., Ready, N., Spigel, D.R., Ramalingam, S.S., Paz-Ares, L.G., Gainor, J.F., Ahmed, S., Reck, M., Maio, M., O’Byrne, K.J., Memaj, A., Nathan, F., Tran, P., Hellmann, M.D., Brahmer, J.R.

Volltext

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECO... von Brodowicz, T., Ciuleanu, T.E., Radosavljevic, D., Shacham-Shmueli, E., Vrbanec, D., Plate, S., Mrsic-Krmpotic, Z., Dank, M., Purkalne, G., Messinger, D., Zielinski, C.C.

Volltext

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial von Borghaei, H, O'Byrne, K J, Paz-Ares, L, Ciuleanu, T-E, Yu, X, Pluzanski, A, Nagrial, A, Havel, L, Kowalyszyn, R D, Valette, C A, Brahmer, J R, Reck, M, Ramalingam, S S, Zhang, L, Ntambwe, I, Rabindran, S K, Nathan, F E, Balli, D, Wu, Y-L

Volltext

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study von Ferris, R.L., Haddad, R., Even, C., Tahara, M., Dvorkin, M., Ciuleanu, T.E., Clement, P.M., Mesia, R., Kutukova, S., Zholudeva, L., Daste, A., Caballero-Daroqui, J., Keam, B., Vynnychenko, I., Lafond, C., Shetty, J., Mann, H., Fan, J., Wildsmith, S., Morsli, N., Fayette, J., Licitra, L.

Volltext

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanc... von Del Campo, J. M., Roszak, A., Bidzinski, M., Ciuleanu, T. E., Hogberg, T., Wojtukiewicz, M. Z., Poveda, A., Boman, K., Westermann, A. M., Lebedinsky, C.

Volltext

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 von Spigel, D.R., Vicente, D., Ciuleanu, T.E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Luft, A., Wolf, J., Antonia, S., Nakagawa, K., Fairchild, J., Baudelet, C., Pandya, D., Doshi, P., Chang, H., Reck, M.

Volltext

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer von Carbone, David P, Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M, Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T. Jeroen N, Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M, Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R, Villaruz, Liza C, Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J, Bhagavatheeswaran, Prabhu, Chen, Allen C, Socinski, Mark A

Volltext

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lun... von Camerini, A., Morabito, A., Montanino, A., Bernabé, R., Grossi, F., Ramlau, R., Ciuleanu, T.-E., Ceresoli, G.-L., Pasello, G., de Marinis, F., Bosch-Barrera, J., Laundreau, P., Gautier, S., Ta Thanh Minh, C., Kowalski, D.

Volltext

Knowledge, attitudes and practices related to the COVID-19 outbreak among Romanian adults with cancer: a cross-sectional national survey von Gheorghe, A.S., Negru, Ş.M., Nițipir, C., Mazilu, L., Marinca, M., Gafton, B., Ciuleanu, T.E., Schenker, M., Dragomir, R.D., Gheorghe, A.D., Stovicek, P.O., Bandi-Vasilica, M., Boț, A.C., Mihăilă, R.I., Zob, D.L., Kajanto, A.L., Stănculeanu, D.L.

Volltext

Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind,... von Ciuleanu, T.-E., Bodoky, G., Garcia-Carbonero, R., García Alfonso, P., Van Cutsem, E., Muro, K., Mytelka, D., Lipkovich, O., Ferry, D., Sashegyi, A., Nasroulah, F., Tabernero, J.

Volltext

Mutation profiles of nasopharyngeal carcinomas in South-Eastern European patients von Fountzilas, G., Psyrri, A., Giannoulatou, E., Kouvatseas, G., Rontogianni, D., Ciuleanu, E., Ciuleanu, T.-E., Resiga, L., Zaramboukas, T., Bobos, M., Chrisafi, S., Tsolaki, E., Papadopoulou, K., Markou, K., Charalambakis, N., Koutras, A., Kalogera-Fountzila, A., Skondra, M., Pectasides, D., Kotoula, V.

Volltext

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, ad... von M Del Campo, J, Roszak, A, Bidzinski, M, Ciuleanu, T E, Högberg, Thomas, Wojtukiewicz, M Z, Poveda, A, Boman, K, Westermann, A M, Lebedinsky, C

Volltext

PD-029Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial von Yoshino, T, Obermannova, R, Bodoky, G, Garcia-Carbonero, R, Ciuleanu, T-E, Portnoy, D, Kim Tae, W, Hsu, Y, Yang, L, Ferry, D, Nasroulah, F, Tabernero, J

Volltext

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year... von Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.

Volltext

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer von Forde, Patrick M., Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M., Felip, Enriqueta, Broderick, Stephen R., Brahmer, Julie R., Swanson, Scott J., Kerr, Keith, Wang, Changli, Ciuleanu, Tudor-Eliade, Saylors, Gene B., Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke-Neng, Liberman, Moishe, Vokes, Everett E., Taube, Janis M., Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y., Girard, Nicolas

Volltext

Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors? von Radulescu, D, Buzdugan, E, Ciuleanu, T E, Todor, N, Stoicescu, L

Volltext